Published on
May 4, 2025
- 16:45 GMT
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, …
Distribution channels:
Science, Technology
...
